JK 07
Alternative Names: JK-07; SAL-007Latest Information Update: 29 Jan 2025
At a glance
- Originator SalubrisBio
- Class Heart failure therapies; Monoclonal antibodies; Neuregulins; Peptides; Recombinant fusion proteins
- Mechanism of Action ERBB 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Heart failure
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 22 Jan 2025 Interim efficacy and adverse event data from the phase IIb RENEU-HF trial in Heart failure released by Salubris Biotherapeutics
- 24 Apr 2024 JK 07 is still in phase I development in Heart-failure (In the elderly, In adults) in USA (IV, Infusion) (NCT04210375)
- 22 Apr 2024 Salubris Biotherapeutics plans a phase II trial for Heart failure (with preserved ejection fraction (HFpEF) in 2H of 2023